Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

June was a positive month for BB Biotech and the biotech sector in general. The positive momentum in the biotech sector was partly driven by the FDA’s approval of Aduhelm, the first novel therapy approved for Alzheimer’s disease since 2003. This event was an important milestone for Biogen, one of BB Biotech´s portfolio companies, and served as a catalyst for the sector. Despite the ongoing global COVID-19 situation and appearance of new viral variants, the majority of biotech companies are operating normally and have not been materially affected the pandemic. In early June, we held a virtual version of our semi-annual strategy meeting, and the BB Biotech Board and team remain very comfortable with our overall portfolio composition.

BB Biotech Update June 2021

June was a positive month for BB Biotech and the biotech sector in general. The positive momentum in the biotech sector was partly driven by the FDA’s approval of Aduhelm, the first novel therapy approved for Alzheimer’s disease since 2003. This event was an important milestone for Biogen, one of BB Biotech´s portfolio companies, and served as a catalyst for the sector. Despite the ongoing global COVID-19 situation and appearance of new viral variants, the majority of biotech companies are operating normally and have not been materially affected the pandemic. In early June, we held a virtual version of our semi-annual strategy meeting, and the BB Biotech Board and team remain very comfortable with our overall portfolio composition.
05.06.2021 - BB Biotech